Heron Therapeutics Company Profile (NASDAQ:HRTX)

About Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics logoHeron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:HRTX
  • CUSIP: N/A
  • Web: www.herontx.com
Average Prices:
  • 50 Day Moving Avg: $14.59
  • 200 Day Moving Avg: $14.29
  • 52 Week Range: $12.21 - $24.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.48
  • P/E Growth: -0.17
Profitability:
  • Return on Equity: -485.29%
  • Return on Assets: -172.14%
Debt:
  • Debt-to-Equity Ratio: 0.49%
  • Current Ratio: 4.91%
  • Quick Ratio: 4.79%
Misc:
  • Average Volume: 910,652 shs.
  • Beta: 2.05
 
Frequently Asked Questions for Heron Therapeutics (NASDAQ:HRTX)

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) announced its earnings results on Wednesday, May, 10th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.94) by $0.06. The firm earned $3.63 million during the quarter, compared to analyst estimates of $1.96 million. View Heron Therapeutics' Earnings History.

Where is Heron Therapeutics' stock going? Where will Heron Therapeutics' stock price be in 2017?

10 equities research analysts have issued 1-year price objectives for Heron Therapeutics' stock. Their forecasts range from $21.00 to $45.00. On average, they anticipate Heron Therapeutics' stock price to reach $33.13 in the next twelve months. View Analyst Ratings for Heron Therapeutics.

What are analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:

  • 1. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (7/12/2017)
  • 2. Cowen and Company analysts commented, "Earlier today Heron stock dropped as much as 8.5% on seemingly no news." (5/26/2017)
  • 3. Cantor Fitzgerald analysts commented, "Expensive 1Q: HRTX reported 1Q17 EPS of ($1.00), below our estimated ($0.83). The difference is mainly attributed to higher than expected R&D spend, though we believe that should taper off through the year, providing some flexibility in cash runway. HRTX finished the quarter with $165M in cash." (5/11/2017)
  • 4. Needham & Company LLC analysts commented, "We initiate coverage of Heron Therapeutics, a commercial-stage specialty biopharma focused on novel extended-release injectables, at Buy with a $28 PT. HRTX made the transition to a commercial co. in 4Q16 with the launch of Sustol for CINV. Cinvanti, on file with FDA (likely 4Q17 PDUFA), will round out the CINV franchise. The main value driver, HTX-011, is an extended-release combination of bupivacaine/meloxicam in development for post-op pain management. HTX-011 successfully completed a comprehensive ph 2 program in various surgical procedures demonstrating superior efficacy to placebo and bupivacaine. HTX-011 will begin ph 3 development in 2017. Our valuation looks at the differentiated CINV assets and cash balance (~$215MM) as a floor value for HRTX, while the potential of HTX-011 remains mostly undervalued." (2/27/2017)

Who are some of Heron Therapeutics' key competitors?

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the folowing people:

  • Kevin C. Tang, Independent Chairman of the Board
  • Robert Harvey Rosen, President, Director
  • Barry D. Quart Pharm.D., Chief Executive Officer, Director
  • Robert E. Hoffman, Chief Financial Officer, Senior Vice President - Finance, Principal Accounting Officer
  • Kimberly J. Manhard, Executive Vice President - Drug Development
  • David L. Szekeres, Senior Vice President, General Counsel, Business Development, Corporate Secretary
  • Michael A. Adam Ph.D., Senior Vice President - Regulatory Affairs and Quality
  • Thomas B. Ottoboni Ph.D., Senior Vice President - Pharmaceutical and Preclinical Research and Development
  • Sean T. Ristine, Vice President - Human Resources
  • Christian Waage, Director

Who owns Heron Therapeutics stock?

Heron Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Fox Run Management L.L.C. (0.00%) and Searle & CO. (0.00%). Company insiders that own Heron Therapeutics stock include Kevin C Tang, Kimberly Manhard and Robert Rosen. View Institutional Ownership Trends for Heron Therapeutics.

Who bought Heron Therapeutics stock? Who is buying Heron Therapeutics stock?

Heron Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C. and Searle & CO.. View Insider Buying and Selling for Heron Therapeutics.

How do I buy Heron Therapeutics stock?

Shares of Heron Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of Heron Therapeutics stock can currently be purchased for approximately $16.90.


MarketBeat Community Rating for Heron Therapeutics (NASDAQ HRTX)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  282 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  359
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Heron Therapeutics (NASDAQ:HRTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 10 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $33.13 (96.01% upside)

Analysts' Ratings History for Heron Therapeutics (NASDAQ:HRTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2017AegisReiterated RatingBuy$33.00LowView Rating Details
7/14/2017Jefferies Group LLCReiterated RatingBuy$26.00LowView Rating Details
6/26/2017Cantor FitzgeraldReiterated RatingOverweightHighView Rating Details
5/26/2017Cowen and CompanyReiterated RatingBuy$40.00HighView Rating Details
5/12/2017Noble FinancialReiterated RatingBuyMediumView Rating Details
2/27/2017Needham & Company LLCInitiated CoverageBuy -> Buy$28.00N/AView Rating Details
1/5/2017Leerink SwannSet Price TargetBuy$21.00N/AView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$41.00N/AView Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$45.00N/AView Rating Details
9/24/2015Bank of America CorporationBoost Price TargetBuy$54.00N/AView Rating Details
(Data available from 7/25/2015 forward)

Earnings

Earnings History for Heron Therapeutics (NASDAQ:HRTX)
Earnings by Quarter for Heron Therapeutics (NASDAQ:HRTX)
Earnings History by Quarter for Heron Therapeutics (NASDAQ HRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.94)($1.00)$1.96 million$3.63 millionViewN/AView Earnings Details
2/23/2017Q4 2016($1.17)($1.22)$1.07 million$1.28 millionViewN/AView Earnings Details
11/8/2016Q3 2016($1.17)($1.24)ViewN/AView Earnings Details
8/8/2016Q2($0.96)($1.17)ViewN/AView Earnings Details
5/5/2016Q1($0.92)($0.92)ViewN/AView Earnings Details
2/19/2016Q4($0.64)($0.87)ViewN/AView Earnings Details
11/6/2015Q3($0.67)($0.63)ViewN/AView Earnings Details
8/7/2015Q2 2015($0.65)($0.74)ViewN/AView Earnings Details
5/8/2015Q115($0.64)($0.70)ViewN/AView Earnings Details
3/13/2015Q4 2014($0.69)($0.71)ViewN/AView Earnings Details
11/6/2014Q3 2014($0.69)($0.66)ViewN/AView Earnings Details
8/4/2014Q2 2014($0.62)($0.78)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.58)($0.74)ViewN/AView Earnings Details
3/5/2014($0.53)($0.75)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Heron Therapeutics (NASDAQ:HRTX)
2017 EPS Consensus Estimate: ($3.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.86)($0.86)($0.86)
Q2 20172($1.04)($0.99)($1.02)
Q3 20172($0.99)($0.80)($0.90)
Q4 20172($0.99)($0.72)($0.86)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Heron Therapeutics (NASDAQ:HRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Heron Therapeutics (NASDAQ:HRTX)
Insider Ownership Percentage: 20.31%
Insider Trades by Quarter for Heron Therapeutics (NASDAQ:HRTX)
Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)
Insider Trades by Quarter for Heron Therapeutics (NASDAQ:HRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/24/2017Kimberly ManhardVPSell21,542$15.33$330,238.86View SEC Filing  
1/19/2017Kevin C TangDirectorBuy2,459,016$12.20$29,999,995.20View SEC Filing  
8/10/2016Robert RosenInsiderSell100,000$23.30$2,330,000.00View SEC Filing  
4/21/2016Robert RosenPresidentSell200,000$23.23$4,646,000.00View SEC Filing  
6/10/2015Kevin C TangDirectorBuy121,212$24.75$2,999,997.00View SEC Filing  
6/2/2015Kevin C TangDirectorBuy150,000$20.62$3,093,000.00View SEC Filing  
6/1/2015Kimberly ManhardDirectorSell2,708$21.17$57,328.36View SEC Filing  
6/25/2014Barry D QuartCEOBuy10,000$11.75$117,500.00View SEC Filing  
6/25/2014Kevin C TangDirectorBuy510,638$11.75$5,999,996.50View SEC Filing  
11/20/2013Barry D QuartCEOBuy1,000,000$0.40$400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Heron Therapeutics (NASDAQ:HRTX)
Latest Headlines for Heron Therapeutics (NASDAQ:HRTX)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Heron Therapeutics, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 11:08 PM
americanbankingnews.com logoZacks: Analysts Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $4.53 Million
www.americanbankingnews.com - July 20 at 3:48 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Earnings of -$0.95 Per Share
www.americanbankingnews.com - July 18 at 9:55 AM
americanbankingnews.com logoHeron Therapeutics, Inc. (NASDAQ:HRTX) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - July 15 at 3:35 PM
finance.yahoo.com logoETFs with exposure to Heron Therapeutics, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 12:43 AM
nasdaq.com logoHRTX Crosses Above Key Moving Average Level
www.nasdaq.com - July 14 at 2:53 AM
seekingalpha.com logoHeron Therapeutics Shows Potential In The Chemotherapy-Induced-Nausea Market
seekingalpha.com - July 10 at 7:34 PM
finance.yahoo.com logoHeron Therapeutics, Inc. – Value Analysis (NASDAQ:HRTX) : July 7, 2017
finance.yahoo.com - July 8 at 11:30 AM
finance.yahoo.com logoHeron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : July 6, 2017
finance.yahoo.com - July 7 at 6:14 AM
americanbankingnews.com logoHeron Therapeutics, Inc. (NASDAQ:HRTX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 3 at 6:52 PM
americanbankingnews.com logoHeron Therapeutics, Inc. Expected to Post FY2017 Earnings of ($3.32) Per Share (HRTX)
www.americanbankingnews.com - June 28 at 8:02 AM
americanbankingnews.com logoHeron Therapeutics, Inc. Forecasted to Post FY2018 Earnings of ($2.23) Per Share (HRTX)
www.americanbankingnews.com - June 27 at 10:14 AM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - June 24 at 11:32 PM
americanbankingnews.com logo Brokerages Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $4.53 Million
www.americanbankingnews.com - June 24 at 11:02 AM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) Expected to Post Earnings of -$1.01 Per Share
www.americanbankingnews.com - June 22 at 8:44 AM
finance.yahoo.com logoHeron Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HRTX-US : June 20, 2017
finance.yahoo.com - June 20 at 3:16 PM
americanbankingnews.com logoHead to Head Review: Heron Therapeutics (HRTX) and Novartis AG (NVS)
www.americanbankingnews.com - June 12 at 10:50 AM
seekingalpha.com logoHeron Therapeutics (HRTX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 7 at 5:19 PM
americanbankingnews.com logoHeron Therapeutics Inc (HRTX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - June 6 at 6:41 PM
businesswire.com logoHeron Therapeutics to Present at the Jefferies 2017 Healthcare Conference - Business Wire (press release)
www.businesswire.com - May 31 at 8:40 AM
finance.yahoo.com logoHeron Therapeutics to Present at the Jefferies 2017 Healthcare Conference
finance.yahoo.com - May 30 at 5:37 PM
finance.yahoo.com logoHeron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : May 29, 2017
finance.yahoo.com - May 29 at 9:49 AM
americanbankingnews.com logo$4.53 Million in Sales Expected for Heron Therapeutics Inc (HRTX) This Quarter
www.americanbankingnews.com - May 28 at 7:48 AM
americanbankingnews.com logoHeron Therapeutics Inc (HRTX) Short Interest Update
www.americanbankingnews.com - May 27 at 7:12 AM
americanbankingnews.com logo-$1.01 Earnings Per Share Expected for Heron Therapeutics Inc (HRTX) This Quarter
www.americanbankingnews.com - May 26 at 10:19 PM
finance.yahoo.com logoOpioids are ravaging the U.S., but they’re still the best pain drug we’ve got
finance.yahoo.com - May 26 at 6:26 PM
americanbankingnews.com logoHeron Therapeutics Inc (HRTX) Earns Buy Rating from Cowen and Company
www.americanbankingnews.com - May 26 at 2:52 PM
americanbankingnews.com logoResearch Analysts Offer Predictions for Heron Therapeutics Inc's Q2 2017 Earnings (HRTX)
www.americanbankingnews.com - May 15 at 7:46 AM
americanbankingnews.com logoHeron Therapeutics Inc (HRTX) Rating Reiterated by Noble Financial
www.americanbankingnews.com - May 13 at 11:32 AM
finance.yahoo.com logoHeron Therapeutics, Inc. – Value Analysis (NASDAQ:HRTX) : May 12, 2017
finance.yahoo.com - May 12 at 6:26 PM
americanbankingnews.com logoHeron Therapeutics Inc (HRTX) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 11 at 10:04 PM
americanbankingnews.com logoHeron Therapeutics' (HRTX) "Buy" Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - May 11 at 9:36 PM
finance.yahoo.com logoHeron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : May 11, 2017
finance.yahoo.com - May 11 at 6:19 PM
finance.yahoo.com logoHeron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress
finance.yahoo.com - May 10 at 6:34 PM
businesswire.com logoHeron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate ... - Business Wire (press release)
www.businesswire.com - May 10 at 1:33 PM
businesswire.com logoHeron Therapeutics to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference - Business Wire (press release)
www.businesswire.com - May 10 at 1:33 PM
marketbeat.com logoHeron Therapeutics reports 1Q loss
marketbeat.com - May 10 at 8:33 AM
finance.yahoo.com logoHeron Therapeutics to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
finance.yahoo.com - May 9 at 5:31 PM
americanbankingnews.com logoSomewhat Favorable Media Coverage Somewhat Unlikely to Affect Heron Therapeutics (HRTX) Share Price
www.americanbankingnews.com - May 9 at 12:50 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Heron Therapeutics Inc (HRTX) Will Post Quarterly Sales of $1.96 Million
www.americanbankingnews.com - May 5 at 3:32 PM
americanbankingnews.com logoHeron Therapeutics Inc (HRTX) Expected to Announce Earnings of -$0.94 Per Share
www.americanbankingnews.com - May 3 at 12:02 PM
americanbankingnews.com logoHeron Therapeutics (HRTX) Earns Coverage Optimism Score of 0.20
www.americanbankingnews.com - May 3 at 1:04 AM
americanbankingnews.com logoHeron Therapeutics Inc (HRTX) Short Interest Up 1.5% in April
www.americanbankingnews.com - April 30 at 4:18 PM
americanbankingnews.com logoHeron Therapeutics (HRTX) Receiving Somewhat Favorable Media Coverage, Report Shows
www.americanbankingnews.com - April 29 at 11:09 PM
americanbankingnews.com logoHeron Therapeutics (HRTX) Earns Coverage Optimism Score of 0.28
www.americanbankingnews.com - April 26 at 6:32 PM
americanbankingnews.com logoHeron Therapeutics Inc (HRTX) VP Sells $330,238.86 in Stock
www.americanbankingnews.com - April 24 at 11:06 PM
finance.yahoo.com logoHeron Therapeutics Appoints Robert E. Hoffman as Chief Financial Officer and Senior Vice President, Finance
finance.yahoo.com - April 24 at 5:27 PM
americanbankingnews.com logoHeron Therapeutics (HRTX) Earning Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 23 at 11:25 AM
americanbankingnews.com logoHeron Therapeutics (HRTX) Receives News Sentiment Score of -0.03
www.americanbankingnews.com - April 20 at 5:51 PM
americanbankingnews.com logoHeron Therapeutics Inc (HRTX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 17 at 6:37 PM

Social

Chart

Heron Therapeutics (HRTX) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff